Evidence syntheses in the registry — page 3
140 documents of type evidence synthesis.
Documents
-
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the effect of SS-31 (elamipretide) compared with the comparator used in…
Moderate11 Nov 2025 -
In the population defined for atherosclerotic cardiovascular disease and cardiovascular risk reduction, what is the effect of Semaglutide, oral compared with the…
Moderate01 Nov 2025 -
In adults at elevated cardiovascular risk, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on major adverse cardiovascular events?
High24 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the…
High22 Oct 2025 -
In the population defined for obesity and overweight in adults, what is the effect of CagriSema (cagrilintide with semaglutide) compared with the comparator used in its…
Moderate17 Oct 2025 -
What is the incidence of gastrointestinal adverse events and of discontinuation for adverse events with incretin receptor agonists compared with placebo?
High12 Oct 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the effect of Kisspeptin-10 compared with the comparator…
Moderate11 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with its comparator?
High09 Oct 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Semaglutide compared with the comparator used in its contributing trials on the anchor…
High04 Oct 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on…
High27 Sep 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the effect of GHK-Cu compared with the comparator used in its contributing trials on the…
Low19 Sep 2025 -
In the population defined for adjunctive therapy in type 1 diabetes, what is the effect of Liraglutide compared with the comparator used in its contributing trials on…
Moderate04 Sep 2025 -
In the population defined for obesity and overweight in adults, is the effect of Mazdutide maintained across the full duration of the contributing trials?
Moderate18 Aug 2025 -
In the population defined for type 2 diabetes mellitus, is the effect of Semaglutide, oral maintained across the full duration of the contributing trials?
High06 Aug 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Tirzepatide compared with the comparator used in its contributing trials on the…
High04 Aug 2025 -
In the population defined for obesity and overweight in adults, is the effect of Semaglutide maintained across the full duration of the contributing trials?
High01 Aug 2025 -
What randomised evidence supports mitochondria-targeted peptides in primary mitochondrial disease and in age-related functional decline?
Low25 Jul 2025 -
In the population defined for cutaneous wound healing and tissue repair, what is the incidence of adverse events leading to discontinuation with Thymosin beta-4 compared…
Low24 Jul 2025 -
Does an oral presentation of a glucagon-like peptide-1 receptor agonist achieve an efficacy and tolerability profile comparable with an injectable presentation?
Moderate16 Jul 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Survodutide compared with its…
Moderate15 Jul 2025 -
In the population defined for inflammatory bowel disease and mucosal barrier disorders, what is the effect of Teduglutide compared with the comparator used in its…
Moderate28 Jun 2025 -
In the population defined for obstructive sleep apnoea with obesity, what is the incidence of adverse events leading to discontinuation with Tirzepatide compared with…
High27 Jun 2025 -
In the population defined for growth hormone deficiency and growth-hormone secretagogue pharmacology, what is the incidence of adverse events leading to discontinuation…
Moderate26 Jun 2025 -
What is the evidence for thymic peptides in chronic viral hepatitis, sepsis and non-specific immune support?
Low17 Jun 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Orforglipron compared with its…
Moderate16 Jun 2025 -
In the population defined for type 2 diabetes mellitus, what is the incidence of adverse events leading to discontinuation with CagriSema (cagrilintide with semaglutide)…
Moderate12 Jun 2025 -
What clinical evidence supports the uses under which growth-hormone secretagogues are supplied for research?
Very low26 May 2025 -
In adults with obesity and without type 2 diabetes, what is the effect of a glucagon-like peptide-1 receptor agonist compared with placebo on percentage change in body…
High23 May 2025 -
What proportion of certificates of analysis supplied with research peptides contain the fields required to interpret the reported purity figure?
Moderate20 May 2025 -
In the population defined for obesity and overweight in adults, what is the effect of Retatrutide compared with the comparator used in its contributing trials on the…
Moderate17 May 2025 -
In the population defined for primary mitochondrial myopathy and bioenergetic disorders, what is the incidence of adverse events leading to discontinuation with SS-31…
Moderate14 May 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Semaglutide compared with its…
High08 May 2025 -
In adults with type 2 diabetes, does tirzepatide achieve greater glycaemic and weight effect than semaglutide?
High26 Apr 2025 -
In the population defined for type 2 diabetes mellitus, what is the effect of Mazdutide compared with the comparator used in its contributing trials on the anchor…
Moderate18 Apr 2025 -
In the population defined for heart failure with preserved ejection fraction and obesity, what is the effect of Semaglutide compared with the comparator used in its…
Moderate14 Apr 2025 -
What is known about the direction and magnitude of the difference between sponsor-conducted and independently conducted trials, and how should an evidence body treat a…
Moderate11 Apr 2025 -
In the population defined for immune modulation and adjunctive immunotherapy, what is the incidence of adverse events leading to discontinuation with Thymosin alpha-1…
Moderate30 Mar 2025 -
What proportion of the mass lost during treatment with an incretin receptor agonist is lean rather than fat mass, and does it differ from that lost through caloric…
Low17 Mar 2025 -
Are the trials in the incretin evidence network sufficiently similar to support indirect comparison?
Moderate11 Mar 2025 -
In the population defined for obesity and overweight in adults, what is the incidence of adverse events leading to discontinuation with Retatrutide compared with its…
Moderate10 Mar 2025
page 3 of 4